Ogawa Y
Department of Pharmacology, Juntendo University School of Medicine, Tokyo.
Crit Rev Biochem Mol Biol. 1994;29(4):229-74. doi: 10.3109/10409239409083482.
Recent findings on the ryanodine receptor of vertebrates, a Ca-release channel protein for the caffeine- and ryanodine-sensitive Ca pools, are reviewed in this article. Three distinct genes, i.e., ryr1, ryr2, and ryr3, express different isoforms in specific locations: Ryr1 in skeletal muscle and Purkinje cells of cerebellum; Ryr2 in cardiac muscle and brain, especially cerebellum; Ryr3 in skeletal muscle of nonmammalian vertebrates, the corpus striatum, and limbic cortex of brain, smooth muscles, and the other cells in vertebrates. While only one isoform (Ryr1) is expressed in mammalian skeletal muscles, two isoforms (alpha- and beta-isoforms expressed by ryr1 and ryr3, respectively) are found in nonmammalian vertebrate skeletal muscles. Although the coexistence of two isoforms may merely be related to differentiation and specialization, the biological significance remains to be clarified. Ryanodine receptors in vertebrate skeletal muscles are believed to mediate two different modes of Ca release: Ca(2+)-induced Ca release and action potential-induced Ca release. All results obtained so far with any isoform of ryanodine receptor are related to Ca(2+)-induced Ca release and show very similar characteristics. Ca(2+)-induced Ca release, however, cannot be the underlying mechanism of Ca release on skeletal muscle activation. Susceptibility of the ryanodine receptor's ryanodine-binding activity to modification by physical factors, such as osmolality of the medium, might be related to action potential-induced Ca release. A hypothesis of molecular interaction in view of the plunger model of action potential-induced Ca release is discussed, suggesting that the model could be compatible with Ryr1 and Ryr3, but incompatible with Ryr2. The functional relevance of ryanodine receptor isoforms, especially Ryr3, in brain also remains to be clarified. Among ryr1 gene-related diseases, malignant hyperthermia was the first to be identified; however, there is still the possibility of involvement of the other genes. Central core disease has been added to the list recently. A molecular approach for the diagnosis and treatment of diseases is now in progress.
本文综述了脊椎动物兰尼碱受体的最新研究发现,该受体是一种对咖啡因和兰尼碱敏感的钙池的钙释放通道蛋白。三个不同的基因,即ryr1、ryr2和ryr3,在特定位置表达不同的亚型:ryr1在骨骼肌和小脑浦肯野细胞中表达;ryr2在心肌和大脑,尤其是小脑中表达;ryr3在非哺乳动物脊椎动物的骨骼肌、纹状体以及大脑的边缘皮质、平滑肌和脊椎动物的其他细胞中表达。虽然在哺乳动物骨骼肌中仅表达一种亚型(Ryr1),但在非哺乳动物脊椎动物骨骼肌中发现了两种亚型(分别由ryr1和ryr3表达的α-和β-亚型)。尽管两种亚型的共存可能仅与分化和特化有关,但其生物学意义仍有待阐明。脊椎动物骨骼肌中的兰尼碱受体被认为介导两种不同的钙释放模式:钙诱导的钙释放和动作电位诱导的钙释放。迄今为止,用兰尼碱受体的任何亚型获得的所有结果都与钙诱导的钙释放有关,并且表现出非常相似的特征。然而,钙诱导的钙释放不可能是骨骼肌激活时钙释放的潜在机制。兰尼碱受体的兰尼碱结合活性对诸如培养基渗透压等物理因素修饰的敏感性,可能与动作电位诱导的钙释放有关。讨论了基于动作电位诱导的钙释放的柱塞模型的分子相互作用假说,表明该模型可能与Ryr1和Ryr3兼容,但与Ryr2不兼容。兰尼碱受体亚型,尤其是Ryr3在大脑中的功能相关性也有待阐明。在与ryr1基因相关的疾病中,恶性高热是最早被发现的;然而,其他基因仍有可能参与其中。中央轴空病最近也被列入该名单。目前正在进行针对疾病诊断和治疗的分子方法研究。